Fatal Intra-Alveolar Hemorrhage After Rituximab in a Patient with non-Hodgkin Lymphoma

References

• Winkler, U., Jensen, M., Manzke, O., etal. (1999) "Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody(rituximab, IDEC-C2B8)", Blood, 94, 2217 — 2224.
   Google Scholar
• Shimoni, A., et al. (2003) "Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma", Br. J. HaematoL, 122, 457–464.
   Web of Science ®Google Scholar
• Maloney, D.G., Smith, B. and Rose, A. (2002) "Rituximab: mechanism of action and resistance", Semin. OncoL, 29, 2–9.
   Google Scholar
• Lowndes, S., Darby, A., Mead, G. and Lister, A. (2002) "Stevens—Johnson syndrome after treatment with rituximab", Ann. OncoL, 13, 1948 — 1950.
   Web of Science ®Google Scholar
• Jourdan, E., Topart, D., Richard, B., et al. (2003) "Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder", Leuk. Lymphoma, 44, 889–890.
   PubMed Web of Science ®Google Scholar
• Voog, E., Morschhauser, F. and Solal-Celigny, P. (2003) "Neu-tropenia in patients treated with rituximab", N. Engl. J. Med., 348, 2691–2694.
   Google Scholar
• Dereure, O., Navarro, R., Rossi, J.F. and Guilhou, J.J. (2001) "Rituximab-induced vasculitis", Dermatology, 203, 83–84.
   PubMed Web of Science ®Google Scholar
• Kanelli, S., Ansell, S.M., Habermann, TM., et al. (2001) "Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis", Leuk. Lymphoma, 42, 1329–1337.
   PubMed Web of Science ®Google Scholar
• Burton, C., Kaczmarski, R. and Jan-Mohamed, R. (2003) "Inter-stitial pneumonitis related to rituximab therapy", N. Engl. J. Med., 348, 2690–2691.
   Google Scholar
• Byrd, J.C., Peterson, B.L., Morrison, V.A., et al. (2002) "Rando-mized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)", Blood, 101, 6–14.
   Google Scholar
• Hainsworth, J.D., Litchy, S., Lamb, MR., et al. (2003) "First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial", Clin. Lymphoma, 4, 36–42.
   Web of Science ®Google Scholar
• Genetech Report, Rituxan and Pulmonary Events, 2003.
   Google Scholar
• van der Kolk, L.E., Grillo-Lopez, A.J., Baars, J.W., et al. (2001) "Complement activation plays a key role in the side-effects of rituximab treatment", Br. J. HaematoL, 115, 807–811.
   PubMed Web of Science ®Google Scholar
• Wing, M.G., Moreau, T., Greenwood, J., et al. (1996) "Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD! 1 a/CD18 (LFA-1) on NK cells", J. Clin. Invest., 98, 2819–2826.
   Google Scholar
• Moreau, T., Coles, A., Wing, M., et al. (1996) "CAMPATH-IH in multiple sclerosis", Mult. Scler., 1, 357–365.
   PubMedGoogle Scholar
• Gaston, R.S., Deierhoi, M.H., Patterson, T., et al. (1991) "OKT3 first-dose reaction: association with T cell subsets and cytokine release", Kidney Int., 39, 141–148.
   PubMed Web of Science ®Google Scholar
• Headley, AS., Tolley, E. and Meduri, G.U. (1997) "Infections and the inflammatory response in acute respiratory distress syndrome", Chest, 111, 1306— 1321.
   Google Scholar
• Griffin, G.E. (1998) "Cytokines involved in human septic shock—the model of the Jarisch-Herxheimer reaction", J. Antimicrob. Chemother., 41, 25–29.
   Web of Science ®Google Scholar
• Selenko, N., Maidic, O., Draxier, S., et al. (2001) "CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocy-tosis by dendritic cells and cross-priming of CD8 + cytotoxic T cells", Leukemia, 15, 1619–1626.
   Web of Science ®Google Scholar
• Hultin, L.E., Hausner, MA., Hultin, P.M. and Giorgi, J.V. (1993) "CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes", Cytometry, 14, 196–204.
   PubMedGoogle Scholar
• Algino, K.M., Thomason, R.W., King, D.E., et al. (1996) "CD20 (pan-B cell antigen) expression on bone marrow-derived T cells", Am. J. Clin. Pathol., 106, 78–81.
   Web of Science ®Google Scholar
• Warzynski, Mi., Graham, D.M., Axtell, R.A., et al. (1994) "Low level CD20 expression on T cell malignancies", Cytometry, 15, 88 — 92.
   Google Scholar
• Murayama, J., Yoshizawa, Y., Ohtsuka, M. and Hasegawa S. (1993) "Lung fibrosis in hypersensitivity pneumonitis. Association with CD4 + but not CD8 + cell dominant alveolitis and insidious onset", Chest, 104, 38–43.
   PubMed Web of Science ®Google Scholar
• Tada, S., Namba, J., Sugimoto, K., et al. (1992) "Studies on the T-cell subset in lung tissue and BALF from patients with interstitial pneumonia", Arerugi, 41, 577–583.
   Google Scholar
• Salaffi, F., Manganelli, P., Carotti, M., et al. (1997) "Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature", Clin. Rheumatol., 16, 296–304.
   Web of Science ®Google Scholar
• Tomichi, N., Yagawa, K., Takayama, K., et al. (1989) "Immuno-histochemical study of T cell subsets in lung tissue and in BALF of patients with farmer's lung disease", Arerugi, 38, 508–512.
   Google Scholar
• Shimizu, S., Yoshinouchi, T., Ohtsuki, Y., et al. (2002) "The appearance of S-100 protein-positive dendritic cells and the distribution of lymphocyte subsets in idiopathic nonspecific inter-stitial pneumonia", Respir. Med., 96, 770–776.
   Web of Science ®Google Scholar
• Yoshioka, Y., Ohwada, A., Dambara, T. and Fukuchi, Y. (2002) "CD4 + T cells in lung tissue predict responsiveness to cyclosporin A in interstitial pneumonia", Respirology, 7, 299–304.
   PubMed Web of Science ®Google Scholar